Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.

BACKGROUND AND AIMS

Hepatic artery infusion chemotherapy (HAIC) has been a long-standing intervention for hepatocellular carcinoma (HCC). Despite positive clinical outcomes, its inclusion in guidelines remains limited due to a lack of evidence-based support. This study aims to identify optimal target populations for HAIC and validate associations between intermediate endpoints with overall survival (OS).

METHODS

Following PRISMA guidelines, a comprehensive search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The primary search strategy was based on medical subject headings terms (MeSH) using 'Hepatic arterial infusion chemotherapy', 'HAIC', 'Sorafenib', 'Nexavar', 'hepatocellular carcinoma', 'HCC', 'Liver cancer', combined with free text words. Data extraction, quality assessment, and analysis were performed according to preregistered protocol.

RESULTS

A total of 26 studies, 6456 HCC patients were included for analysis (HAIC, n =2648; Sorafenib, n =3808). Pooled outcomes revealed that Sorafenib demonstrated better OS only in patients who were refractory to trans-arterial chemoembolization (TACE) (HR=1.32, 95% CI [1.01-1.73]), in other subgroups or overall HCC population HAIC consistently outperformed Sorafenib in patients' survival. Radiologically, higher response rates in the HAIC group does not necessarily translate into survival improvement, but the hazard ratios (HRs) of 1-year-OS (R 2 =0.41, P =0.0044) and 1-year-progression free survival (1y-PFS) (R 2 =0.77, P =0.0002) strongly correlated with the patients OS. Meanwhile, larger tumour size (HR=1.86, 95% CI [1.12-3.1, 95%), heavier tumour burden (HR=2.32, 95% CI [1.33-4.02), existence of MVI or EHS (HR=1.65, 95% CI [1.36-2]; HR=1.60, 95% CI [1.19-2.14]), and AFP >400 ng/ml (HR=1.52, 95% CI [1.20-1.92]) were identified as independent risk factors for OS, while HAIC treatment (HR=0.54, 95% CI [0.35-0.82]) and lower BCLC stage (HR=0.44, 95% CI [0.28-0.69]) were potential protective factors for HCC patients.

CONCLUSION

HAIC monotherapy appears noninferior to Sorafenib in HCC treatment, with potential benefits in specific subgroups. The robust correlation between 1y-OS/1y-PFS and OS, alongside identified risk and protective factors from the present study, offers valuable insights for designing future large prospective studies in this field.